Skip to content
Inciteful Med

Treatment Strategies and PRRT

Last updated:

Treatment for endocrine and neuroendocrine tumors depends on the tumor type, grade, and whether it produces hormones. Standard options include surgical removal, symptom-controlling medications like somatostatin analogs (SSAs), and targeted radiation therapies like PRRT.

Key Takeaways

  • • Surgical resection is the primary treatment goal and can potentially cure localized neuroendocrine tumors.
  • • Patients with functional carcinoid tumors require specific IV medications during surgery to prevent a life-threatening carcinoid crisis.
  • • Somatostatin analogs (SSAs) help control hormone-related symptoms like flushing and diarrhea while slowing tumor growth.
  • • PRRT is a specialized targeted radiation therapy that attacks tumor cells with somatostatin receptors.
  • • Fast-growing neuroendocrine carcinomas (NECs) are typically treated with traditional chemotherapy combinations.

Treating endocrine and neuroendocrine tumors requires a highly personalized approach. Because these tumors can arise from various glands (thyroid, pituitary, neuroendocrine system), and because they may or may not produce hormones, your “roadmap” for treatment will depend heavily on the tumor’s specific origin, its grade, and whether it has spread [1][2][3].

Surgery: The Primary Goal

Whenever possible, surgical resection (removing the tumor) is the gold standard and often the only way to potentially cure the disease [4][5]. If the tumor is localized—meaning it hasn’t spread—surgery can often remove all traces of the disease [3]. Even if the tumor cannot be entirely removed, surgeons may perform “debulking” to reduce the tumor’s size, which can dramatically help manage symptoms [4].

  • Safety Warning for Carcinoid Syndrome: For patients with functional carcinoid tumors, the physical stress of surgery or anesthesia can trigger a severe Carcinoid Crisis—a life-threatening spike in symptoms. Ensure your surgical team plans to administer prophylactic IV octreotide before and during your procedure to protect you [6].

Radioactive Iodine (RAI) for Thyroid Cancer

For patients with differentiated thyroid cancer (such as Papillary Thyroid Carcinoma, the most common endocrine tumor), Radioactive Iodine (RAI) is a standard and highly effective treatment after surgery. Because the thyroid gland naturally absorbs iodine, RAI uses a radioactive form of iodine to destroy any remaining microscopic thyroid tissue or cancer cells, while sparing the rest of the body [7].

Somatostatin Analogs (SSAs): Medical Management

For specific neuroendocrine tumors (NETs) that have spread or cannot be removed, Somatostatin Analogs (SSAs) like octreotide and lanreotide are often the first medical treatment [8][6][9].

  • Symptom Control: These drugs block the release of excess hormones, effectively stopping the “flushing” and diarrhea seen in carcinoid syndrome [6][10][11].
  • Tumor Stabilization: SSAs also have an “antiproliferative” effect, meaning they act like a “brake” to slow down or stabilize tumor growth [12][13][14].

PRRT: Targeted Radiation for Specific NETs

Peptide Receptor Radionuclide Therapy (PRRT), such as Lutetium Lu-177 dotatate, is a highly specialized treatment for specific neuroendocrine tumors (like GI or pancreatic NETs) that have somatostatin receptors (SSTRs) on their surface [15][16].

  • How it works: Think of the DOTATATE as a “key” that only fits into the “locks” (receptors) on the tumor cells. Attached to this key is a small amount of radioactive material (the Lutetium) [15][17].
  • The Result: When the drug is injected, it travels through the blood and “plugs into” the tumor cells, delivering a highly targeted, powerful dose of radiation directly to the tumor while sparing most healthy tissue [15][18][17].
  • Side Effects to Watch: While PRRT is highly targeted, it requires protection protocols. You will receive a simultaneous amino acid infusion to protect your kidneys during treatment. Your care team will also perform regular blood tests to monitor for bone marrow suppression (low blood counts) [19].

Targeted Therapies and Chemotherapy

If SSAs or PRRT are not the right fit, or if the tumor becomes resistant, other options include:

  • Targeted Therapies: Drugs like everolimus (an mTOR inhibitor) or sunitinib (a tyrosine kinase inhibitor) work by blocking the specific pathways and blood supply the tumor needs to grow [20][21].
  • Chemotherapy: For more aggressive, fast-growing tumors (Neuroendocrine Carcinomas or NECs), doctors typically use traditional chemotherapy combinations like cisplatin and etoposide [22][23][24]. These tumors often grow too fast for PRRT or SSAs to be effective [25][26].

Frequently Asked Questions

Can surgery completely cure a neuroendocrine tumor?
If a tumor is localized and hasn't spread, surgical removal is the primary treatment and can potentially cure the disease. When complete removal isn't possible, surgery can still reduce the tumor's size to help manage severe symptoms.
What is a carcinoid crisis during surgery?
For patients with functional carcinoid tumors, the physical stress of surgery or anesthesia can trigger a severe, life-threatening spike in symptoms called a carcinoid crisis. Doctors prevent this by administering an IV medication called octreotide before and during the procedure.
How do somatostatin analogs (SSAs) help treat NETs?
Somatostatin analogs, such as octreotide and lanreotide, block the release of excess hormones to control symptoms like flushing and diarrhea. They also have an antiproliferative effect, meaning they can help slow down or stabilize tumor growth.
What is PRRT and how does it work?
Peptide Receptor Radionuclide Therapy (PRRT) is a targeted radiation treatment for specific neuroendocrine tumors. It uses a drug to seek out somatostatin receptors on tumor cells and deliver radiation directly to them, sparing most healthy tissue.
When is traditional chemotherapy used for neuroendocrine tumors?
Traditional chemotherapy is typically reserved for fast-growing, aggressive tumors known as neuroendocrine carcinomas (NECs). These tumors multiply too quickly for targeted therapies like PRRT or SSAs to be effective.

Questions for Your Doctor

  • • Is my tumor a candidate for surgical removal, or is it considered 'unresectable'?
  • • If I am having surgery, is there a plan in place for prophylactic IV octreotide to prevent Carcinoid Crisis?
  • • If I have differentiated thyroid cancer, will I need Radioactive Iodine (RAI) therapy after surgery?
  • • How will somatostatin analogs (SSAs) help control my symptoms versus slowing the tumor's growth?
  • • Am I a candidate for PRRT, and did my DOTATATE PET scan show enough somatostatin receptors for it to work?
  • • What are the potential side effects of PRRT, and how will my kidneys and bone marrow be protected and monitored?

Questions for You

  • • Am I experiencing 'spells' of symptoms like flushing or diarrhea that would benefit from hormone-blocking injections (SSAs)?
  • • How do I feel about receiving targeted radiation therapies (like RAI or PRRT) that may involve specific hospital protocols?
  • • Have I discussed the 'grade' of my tumor (G1, G2, or G3) with my oncologist to understand how aggressive it might be?
  • • Is my main goal right now to shrink the tumor, stabilize its growth, or manage my daily symptoms?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.

    Boucher JE, Sommers R

    Clinical journal of oncology nursing 2018; (22(5)):565-568 doi:10.1188/18.CJON.565-568.

    PMID: 30239510
  2. 2

    Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.

    Giri S, Sahoo J

    World journal of gastroenterology 2024; (30(12)):1670-1675 doi:10.3748/wjg.v30.i12.1670.

    PMID: 38617746
  3. 3

    Update in the management of gastroenteropancreatic neuroendocrine tumors.

    Sedlack AJH, Varghese DG, Naimian A, et al.

    Cancer 2024; (130(18)):3090-3105 doi:10.1002/cncr.35463.

    PMID: 39012928
  4. 4

    The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

    Bodei L, Ćwikla JB, Kidd M, Modlin IM

    Journal of thoracic disease 2017; (9(Suppl 15)):S1511-S1523 doi:10.21037/jtd.2017.09.82.

    PMID: 29201454
  5. 5

    Carcinoid tumors outside the abdomen.

    Koehler K, Iams WT

    Cancer medicine 2023; (12(7)):7893-7903 doi:10.1002/cam4.5564.

    PMID: 36560885
  6. 6

    New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

    Phan AT, Kunz PL, Reidy-Lagunes DL

    Clinical advances in hematology & oncology : H&O 2015; (13(5 Suppl 5)):1-18; quiz 1 p following 18.

    PMID: 26430956
  7. 7

    [Modern aspects influencing the management of patients with papillary thyroid cancer].

    Skibitskaya MV, Kuznetsov NS

    Khirurgiia 2023; 89-94 doi:10.17116/hirurgia202312189.

    PMID: 38088845
  8. 8

    The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives.

    Lauricella E, Vilisova S, Chaoul N, et al.

    Expert review of neurotherapeutics 2025; (25(2)):245-258 doi:10.1080/14737175.2024.2417419.

    PMID: 39415322
  9. 9

    Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.

    Narayanan S, Kunz PL

    Hematology/oncology clinics of North America 2016; (30(1)):163-77.

    PMID: 26614375
  10. 10

    Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.

    Ryan P, Phan AT, Adelman DT, Iwasaki M

    Clinical journal of oncology nursing 2016; (20(6)):E139-E146 doi:10.1188/16.CJON.E139-E146.

    PMID: 27857269
  11. 11

    Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.

    Alexandraki KI, Karapanagioti A, Karoumpalis I, et al.

    BioMed research international 2017; (2017()):9856140 doi:10.1155/2017/9856140.

    PMID: 29349087
  12. 12

    Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

    Patel M, Tena I, Jha A, et al.

    Frontiers in endocrinology 2021; (12()):625312 doi:10.3389/fendo.2021.625312.

    PMID: 33854479
  13. 13

    [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].

    Bencsiková B

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2016; (29(4)):253-8 doi:10.14735/amko2016253.

    PMID: 27534781
  14. 14

    Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

    Saif MW

    Expert opinion on pharmacotherapy 2016; (17(3)):443-56 doi:10.1517/14656566.2016.1127914.

    PMID: 26635177
  15. 15

    Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

    Hennrich U, Kopka K

    Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

    PMID: 31362406
  16. 16

    A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients.

    Becx MN, Minczeles NS, Brabander T, et al.

    Cancers 2022; (14(23)) doi:10.3390/cancers14235792.

    PMID: 36497273
  17. 17

    Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.

    Severi S, Grassi I, Nicolini S, et al.

    OncoTargets and therapy 2017; (10()):551-557 doi:10.2147/OTT.S97584.

    PMID: 28203088
  18. 18

    177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.

    Das S, Al-Toubah T, El-Haddad G, Strosberg J

    Expert review of gastroenterology & hepatology 2019; (13(11)):1023-1031 doi:10.1080/17474124.2019.1685381.

    PMID: 31652074
  19. 19

    Theragnostics in Neuroendocrine Tumors.

    Rodrigues M, Svirydenka H, Virgolini I

    PET clinics 2021; (16(3)):365-373 doi:10.1016/j.cpet.2021.03.001.

    PMID: 34053580
  20. 20

    Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.

    Dawod M, Gordoa TA, Cives M, et al.

    Current treatment options in oncology 2021; (22(8)):73 doi:10.1007/s11864-021-00863-y.

    PMID: 34185197
  21. 21

    An Update on the Management of Rectal Neuroendocrine Neoplasms.

    Frydman A, Srirajaskanthan R

    Current treatment options in oncology 2024; (25(11)):1461-1470 doi:10.1007/s11864-024-01267-4.

    PMID: 39476215
  22. 22

    Neuroendocrine Carcinomas of the Digestive Tract: What Is New?

    Pellat A, Cottereau AS, Terris B, Coriat R

    Cancers 2021; (13(15)) doi:10.3390/cancers13153766.

    PMID: 34359666
  23. 23

    Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.

    Fazio N, Milione M

    Cancer treatment reviews 2016; (50()):61-67 doi:10.1016/j.ctrv.2016.08.006.

    PMID: 27636009
  24. 24

    Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.

    Urman A, Schonman I, De Jesus-Acosta A

    Current treatment options in oncology 2025; (26(2)):92-102 doi:10.1007/s11864-024-01283-4.

    PMID: 39843688
  25. 25

    PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC).

    Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J

    Journal of neuroendocrinology 2025; (37(3)):e13443 doi:10.1111/jne.13443.

    PMID: 39243213
  26. 26

    Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence.

    Minamimoto R, Kato K, Iwano S, et al.

    Nagoya journal of medical science 2025; (87(4)):607-631 doi:10.18999/nagjms.87.4.607.

    PMID: 41550194

This page provides educational information about treatments for endocrine and neuroendocrine tumors. Always consult your oncologist or endocrinologist to determine the best treatment plan for your specific diagnosis.

Stay up to date

Get notified when new research about Tumor of endocrine glands is published.

No spam. Unsubscribe anytime.